Knights of Columbus Asset Advisors LLC Cuts Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Knights of Columbus Asset Advisors LLC lessened its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,966 shares of the company's stock after selling 11,790 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.08% of Kiniksa Pharmaceuticals worth $1,206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at $1,192,000. JPMorgan Chase & Co. purchased a new position in Kiniksa Pharmaceuticals in the third quarter worth about $4,997,000. Parkman Healthcare Partners LLC grew its holdings in shares of Kiniksa Pharmaceuticals by 16.7% during the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock valued at $18,874,000 after buying an additional 108,102 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $675,000. Finally, SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $355,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Up 2.6 %

NASDAQ KNSA traded up $0.60 during trading hours on Thursday, hitting $23.36. 526,236 shares of the company were exchanged, compared to its average volume of 406,956. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The stock has a 50-day moving average price of $20.58 and a 200 day moving average price of $21.99. The stock has a market cap of $1.70 billion, a PE ratio of -166.85 and a beta of 0.48.

Remove Ads

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to analysts' expectations of $123.42 million. During the same period in the prior year, the firm posted $0.35 earnings per share. Kiniksa Pharmaceuticals's revenue for the quarter was up 46.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $37.17.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,766 shares of company stock worth $2,011,735 in the last ninety days. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.